Founded in November 2020, Suzhou AccuPulse is committed to becoming an international leading platform-based innovative cardiac electrophysiology company. The company has established a research and development team led by well-known electrophysiological experts in the US with R&D centers in Suzhou and in the United States.
Suzhou AccuPulse announced the completion of a nearly CNY 100 million (USD 15 Million) Series A financing round. This round of funding was led by Qianhai FOF, with follow-on participation from existing shareholders Shanghai Biomedical Industry Equity Investment (Chinese: 上海生物医药基金) and Bio Venture (Chinese: 元生创投). The proceeds will be mainly used to advance pipeline clinical trials.
AccuPulse is accelerating and enriching its pipeline portfolio. The company has established nearly 10 pipelines based on new technologies such as pulsed electric field ablation (PFA) and innovative 3D mapping. The company strives to cover the complete patient flow of ablation diagnosis and treatment of arrhythmias such as atrial fibrillation and premature ventricular contractions. To date, the first blockbuster pipeline PFA pulsed electric field ablation system has efficiently completed animal experiments and registered type inspections.
Cardiac electrophysiology technology is mainly used for the treatment of tachyarrhythmias. According to public sources, there is more than 30 million patients in China in 2020. Among them, atrial fibrillation, ventricular arrhythmia, and supraventricular tachycardia are the most prevalent indications.
By applying electromagnetic technology, three-dimensional electrophysiological surgery could achieve precise positioning to shorten the operation time and improve the success rate and safety of the operation. It is gradually replacing two-dimensional technology and become mainstream. Johnson & Johnson, Abbott, and Boston Scientific have long occupied the main market share of 3D ablation surgery by virtue of their innovative advantages.
AccuPulse’s main competitors include MicroPort (Chinese: 微创医疗, HK:00853), APT Medical (Chinese: 惠泰医疗, SHA:688617).